Researchers using FDG PET/CT found that bone sarcoma patients who are histopathologic responders to neoadjuvant treatment exhibited a more significant decrease in tumor FDG-SUVmax than nonresponders. The finding indicates that changes in FDG-SUVmax after neoadjuvant treatment can help determine responders and nonresponders among the patients. "This information could now be applied prospectively to examine whether PET-guided therapeutic decisions affect survival of bone sarcoma patients," the researchers said.

Full Story:

Related Summaries